Why Is BAUSCH HEALTH COS IN (BHC) Stock Up Today?

BHC stock rose 14.26% to $6.89 in a single session driven by the company’s updated guidance and strong Q2 results. The stock’s sharp move reflects the market’s positive reaction to Bausch Health Companies Inc.’s performance and revised expectations for the year. The company’s adjusted earnings per share and revenue both exceeded estimates, signaling improved operational performance.

What Happened

Bausch Health Companies Inc. reported Q2 adjusted earnings per share of $1.26, beating the $1.04 estimate. Revenue for the quarter came in at $2.852 billion, surpassing the $2.661 billion estimate. The company also raised its full-year 2026 sales guidance to a range of $10.790 billion to $11.040 billion, up from the previous range of $10.670 billion to $10.920 billion. This update came ahead of the preliminary estimated sales of $10.773 billion. The company also announced that its PrELIDEL Cream was listed under Alberta’s Public Drug Plan in Canada, adding to the positive momentum.

What The Data Shows

Despite a market capitalization of $2.6 billion and a trailing twelve-month net margin of -10.1%, Bausch Health has shown a 10.1% revenue increase in the TTM period. The stock currently trades within its 52-week range of $4.33 to $8.69. The session’s move was significantly above average volume, though no specific volume figure is provided. The stock’s beta of 0.42 suggests it is less volatile than the broader market.

What To Watch

The company’s next earnings date is not provided, but coverage of the recent developments remains limited to one story in the last 36 hours. Investors should monitor the breadth of analyst coverage and any follow-up guidance from the company in the coming weeks.